A prospective, open-label, multicenter randomized phase-II trial to evaluate the efficacy and safety of a sequential regimen of obinutuzumab (Gazyvaro) followed by obinutuzumab and venetoclax, followed by either standard venetoclax maintenance or MRD guided venetoclax maintenance in first-line patients with CLL and unfit for FCR-like regimens
Latest Information Update: 25 Jul 2023
At a glance
- Drugs Obinutuzumab (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms GIVE
- 15 Jun 2023 Results (n=60) assessing the value of MRD dynamicsin the setting of fixed-duration treatment with venetoclax and obinutuzumab presented at the 28th Congress of the European Haematology Association
- 17 Jun 2022 Results characterizing the cytogenetic, immunogenetic and mutational landscape of IGLV3-21R110 CLL and to assess the predictive impact of this genotype in the context of novel therapies patients enrolled in the HOVON-139/GIVE trial and the Dutch sub-cohort of the HOVON-141/VIsion trial, presented at the 27th Congress of the European Haematology Association.
- 17 Jun 2021 Status changed from recruiting to active, no longer recruiting.